# Annual Survey of Laboratory Testing Practices for *C. difficile* Infection

CDC's Emerging Infections Program - Clostridioides difficile Infection Surveillance

To be co	ompleted by surveillance officer
LABID#:	
Comple	ted By:
Date su	rvey was completed: / /
Is this a	new laboratory?
$\bigcirc$	Yes
	No
	Year added to surveillance:
Is this la	ab in another EIP site?
$\bigcirc$	Yes
	What state?
	LabID in other EIP site:
$\bigcirc$	No
Is this la	b participating in surveillance?
_	Yes
$\bigcirc$	No
How of	en do you receive line lists from this lab?
$\bigcirc$	Daily
$\bigcirc$	Weekly
$\bigcirc$	Monthly
$\bigcirc$	Annually
$\bigcirc$	Never
$\bigcirc$	Other

**Section 1: Laboratory Information** 

Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

Form Approved OMB No. XXX-XXXX

How do	you receive line lists from this lab?
$\bigcirc$	Electronic laboratory reporting (e.g. HL7 messaging)
$\bigcirc$	Fax
$\bigcirc$	Email
	Mail
$\tilde{\bigcirc}$	Secure file transfer
$\tilde{\bigcirc}$	Other
Ü	Specify:
Do you	receive specimens from this lab?
$\bigcirc$	Yes
$\circ$	No
0	is lab audited in 2020? Yes, in person Yes, not in person No, not in catchment No, not audited
	Specify reason:
Is this a	private, commercial lab (e.g. Quest or LabCorp)? Yes No
Types	of facilities in your catchment area served by this lab (select all that apply):
$\bigcirc$	Hospitals
$\sim$	LTACHs
Ō	LTCFs
$\circ$	Outpatient facilities

Form Approved OMB No. XXX-XXXX

# Section 2: Survey To be completed by lab personnel

Pos	itio	n of the staff who responded to the survey:
	$\bigcirc$	Laboratory Supervisor
	$\bigcirc$	Microbiology Supervisor
	$\bigcirc$	Other
		Specify:
Off	site	Testing
	_	
1.	Do	es your laboratory ever send specimens off-site for Clostridioides difficile testing? (Choose one)
	$\bigcirc$	Always (no onsite testing performed)
		LabID of Offsite Lab:
	$\bigcirc$	Regularly, as part of standard testing algorithm
		LabID of Offsite Lab:
		Which tests are done offsite, and at which point in the testing algorithm?
	$\bigcirc$	Not regularly, but when a test ordered by a physician cannot be performed onsite
		Specify tests performed offsite:
	$\bigcirc$	Never (All testing performed onsite)
	$\bigcirc$	Unknown
	$\bigcirc$	Other
	-	Specify:

2. What type and order of testing is routinely used by your laboratory in standard testing for C. difficile? (Enter letter from choices below; choose only one option for each line of testing) 1<sup>st</sup> line of testing: \_\_\_\_\_ 3rd line of testing: \_\_\_\_\_ 3rd line of testing: \_\_\_\_\_ A. EIA Toxin A and B B. EIA for Toxin A only C. EIA for Toxin B only D. EIA Antigen (GDH) E. EIA Toxin A/B and Antigen (Simultaneous testing) F. EIA Other Specify other EIA type: G. Nucleic Acid Amplification (e.g. PCR, Illumigene, Luminex, Biofire) H. Culture I. Cytotoxin J. Other Specify other test type: \_\_\_\_\_ K. No one routine test; clients can order from among several tests Specify types: L. None 2a. Which specimens are used during your 2<sup>nd</sup> line of testing? (Choose one) O Positive by the 1st line of testing Negative by the 1<sup>st</sup> line of testing Specimens with discordant results (e.g. EIA+/GDH- or GDH+/EIA-) All specimens O Do not use 2<sup>nd</sup> line of testing 2b. Which specimens are used during your 3<sup>rd</sup> line of testing? (Choose one) O Positive by the 2<sup>nd</sup> line of testing Negative by the 2<sup>nd</sup> line of testing O Specimens with discordant results (e.g. EIA+/GDH- or GDH+/EIA-) All specimens O not use 3<sup>rd</sup> line of testing 2c. Does your laboratory perform any onsite testing for C. difficile outside of your normal testing algorithm? No, all onsite testing is done according to the testing algorithm specified above Yes, on physician request

Specify tests:

Specify: \_\_\_\_\_

Other

# Testing Kits for CDI

3a.	a. Which EIA test kit is currently used by your laboratory? (Check all that apply)	
		Premier (Meridian) Toxins A & B
		Premier (Meridian) Toxin A
		Remel ProSpecT Toxins A & B
		TechLab Toxins A & B
		Inverness Medical/Wampole Toxins A & B QuikCheck
		Inverness Medical/Wampole QuikCheck Complete (Toxins A & B and Antigen)
		Antigen Testing
		Specify antigen testing kit name/manufacturer:
		Other
		Specify other kit name/manufacturer:
		N/A (Do not use EIA testing)
3b.	. Wh	ich Nucleic Acid Amplification test is currently used by your laboratory? (Check all that apply)
	□ BD-GeneOhm C. difficile	
		BD MAX C. difficile
		Cepheid Xpert C. difficile
		Meridian Illumigene
		Prodesse (Gen-Probe) Progastro CD
		Luminex xTAG GPP
		Biofire Filmarray GI Panel
		Quidel AmpliVue C. difficile Assay
		Great Basin Portrait Toxigenic C. difficile Assay
		Nanosphere Verigene SP
		Other
		Specify other test:
		N/A (Do not use nucleic acid amplification)

# Multiplex GI panels

4a. If y	our laboratory uses a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG
GPP) to	o test for several GI pathogens, does your laboratory suppress the C. diff result so that clinicians cannot
see it?	
	Yes, always
	Yes, at clinician request
	Yes, but will release the result upon clinician request
	Yes, sometimes
	Specify:
	No, clinicians always see C. diff result
	N/A (Do not use multiplexed molecular diagnostic)
4b. If y	our laboratory uses a multiplexed diagnostic and the result is suppressed, where does the suppression
occur?	
	At the multiplexed molecular diagnostic instrument level (the result is not entered into the laboratory
	information management system (LIMS))
	At the laboratory information management system (LIMS) level
	Other
	Specify:
□ N/A (Do not use multiplexed molecular diagnostic or the result is never suppressed)	
Testin	g Codes
	at are the LOINC or internal testing codes associated with the tests your lab currently uses (e.g. LOINC 13957-6, 34713-8, or 54067-4)?  Specify:

6. Has your lab testing algorithm for C. difficile changed since	e January 1, 2020?
○ Yes	
What date did this change occur?//	
○ No	
6a. (If yes) What was your previous type and order of testing	?
(Enter letter from choices below; choose only one option for ed	ach line of testing)
1 <sup>st</sup> line of testing: 2 <sup>nd</sup> line of testing:	3 <sup>rd</sup> line of testing:
A. EIA Toxin A and B	
B. EIA for Toxin A only	
C. EIA for Toxin B only	
D. EIA Antigen (GDH)	
E. EIA Toxin A/B and Antigen (Simultaneous testing)	
F. EIA Other	
Specify other EIA type:	
G. Nucleic Acid Amplification (e.g. PCR, Illumigene, Lum	inex, Biofire)
H. Culture	
I. Cytotoxin	
J. Other	
Specify other test type:	
K. No one routine test; clients can order from among se	veral tests
Specify types:	
L. None	
6b. Which specimens were used during your 2 <sup>nd</sup> line of testir	ng? (Choose one)
O Positive by the 1 <sup>st</sup> line of testing	
<ul> <li>Negative by the 1<sup>st</sup> line of testing</li> </ul>	
<ul> <li>Specimens with discordant results (e.g. EIA +/GDH- or</li> </ul>	GDH+/EIA-)
<ul><li>All specimens</li></ul>	
On not use 2 <sup>nd</sup> line of testing (go to question 6)	
6c. Which specimens were used during your 3 <sup>rd</sup> line of testing	g? (Choose one)
O Positive by the 2 <sup>nd</sup> line of testing	
<ul> <li>Negative by the 2<sup>nd</sup> line of testing</li> </ul>	
O Specimens with discordant results (e.g. EIA+/GDH- or	GDH+/EIA-)
<ul> <li>All specimens</li> </ul>	
On not use 3 <sup>rd</sup> line of testing (go to question 6)	

### **Laboratory Policies**

7. Does	s your lab have a policy to reject stool specimens for C. difficile testing? (Read all options. Check all that
apply)	
	Yes, when stools are formed (formed stools are defined as stools that do NOT take the shape of the container)
	Yes, if there is a stool specimen already positive within 24 hrs of a new stool specimen
	Yes, if there is a stool specimen already positive within 48 hrs of a new stool specimen
	Yes, if there is a stool specimen that tested negative for <i>C. difficile</i> within 48 hours of a new stool specimen
	Yes, will not accept more than one stool specimen in a 24 hr period
	No rejection policy
	Other rejection policies
	Specify other rejection policy:
7a. Has	your rejection policy for stool specimens changed since January 1, 2020?
$\bigcirc$	Yes
	What date did this change occur?///
$\circ$	No

## 8. How many stool samples did you test for C. diff each month in 2020?

Month	Stool samples tested	C. diff+ samples
January		
February		
March		
April		
May		
June		
July		
August		
September		
October		
November		
December		

# Appendix: Common C. difficile Test Kit Names and Manufactures

#### **EIA Toxin A & B**

Wampole\* Toxin A/B Quik Chek

Techlab\* C. difficile Toxin A/B II

BioMerieux Vidas C. difficile Toxin A/B

Meridian Immunocard Toxin A/B

Meridian Premier Toxin A/B

Remel Xpect C. difficile Toxin A/B

Remel ProSpecT Toxin A/B

#### **EIA Antigen (GDH)**

Wampole\* C. difficile Chek-60

Wampole\* C. difficile Quik Chek

Meridian Immunocard C. difficile

#### EIA Toxin A/B and Antigen (Simultaneous Testing)

Wampole\* C. difficile Quik Chek Complete

#### **Nucleic Acid Amplification**

BD-GeneOhm C. difficile

Cepheid Xpert C. difficile

Great Basin Portrait Toxigenic C. difficile Assay

Luminex xTAG Gastrointestinal Pathogen Panel (xTAG GPP)

Meridian BioScience Illumigene

Nanosphere Verigene SP

Prodesse (Gen-Probe) Progastro CD

Quidel AmpliVue C. difficile Assay

#### **EIA for Toxin B Only**

Alere\* C. difficile Toxin B

<sup>\*</sup>Techlab, Inverness Medical, Alere, Wampole may be used interchangeably for these test kits